Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: 24 | Vintage Vibes

NVIDIA (NASDAQ:NVDA) reported record first-quarter fiscal 2027 results, with revenue, operating income and free cash flow all surpassing prior company highs, as executives said demand for AI infrastructure continued to accelerate across hyperscale cloud providers, AI cloud companies, sovereign custo

MarketBeat

e.l.f. Beauty Q4 Earnings Call Highlights

e.l.f. Beauty (NYSE:ELF) reported what executives described as a seventh consecutive year of “industry-leading” results, with fiscal 2026 net sales up 25% and adjusted EBITDA up 13%, while also signaling a more cautious near-term outlook for its core e.l.f. brand. Chairman and Chief Executive Offic

MarketBeat

CCC Intelligent Solutions Enters Next AI Phase as Products Scale With Major Customers

CCC Intelligent Solutions Holdings Inc. Common Stock (NASDAQ:CCC) management said the company is entering its next phase with artificial intelligence moving from evaluation and testing into broader production use across its customer base. Speaking at the JPMorgan Boston TMC Conference, CEO Githesh

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Biosig Technologies Q1 Earnings Call Highlights

Biosig Technologies (NASDAQ:STEX), operating as Streamex Corp, said its first quarter of 2026 marked a transition from product preparation to early commercialization, highlighted by the launch of its tokenized gold product, the payment of initial dividends to holders and the retirement of its conver

MarketBeat

Intuit Q3 Earnings Call Highlights

Intuit (NASDAQ:INTU) reported fiscal third-quarter revenue growth of 10% and raised its full-year outlook, while management outlined plans to reduce the company’s full-time workforce by 17% and adjust its approach to lower-income, price-sensitive tax filers. Chairman and CEO Sasan Goodarzi said the

MarketBeat

Belite Bio Q1 Earnings Call Highlights

Belite Bio (NASDAQ:BLTE) said it has begun a rolling New Drug Application submission to the U.S. Food and Drug Administration for Tinlarebant in Stargardt disease, while also accelerating preparations for a potential commercial launch. On the company’s first-quarter 2026 earnings call, Chairman and

MarketBeat

Booking CEO Sees AI, Connected Trips Driving Long-Term Travel Growth

Booking (NASDAQ:BKNG) Holdings CEO and President Glenn Fogel said the online travel company remains focused on long-term product investment and market-share gains, even as the travel industry faces near-term uncertainty from geopolitical conflict and macroeconomic concerns. Speaking at an investor

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.

MarketBeat

Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances

Beam Therapeutics (NASDAQ:BEAM) Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license application for its sickle cell disease candidate possible as early as the end of this year. Sp

MarketBeat

CorVel Q4 Earnings Call Highlights

CorVel (NASDAQ:CRVL) said revenue and earnings increased in its March quarter and fiscal 2026, as growth in its Network Solutions business, stronger bookings and operating efficiency helped offset a higher effective tax rate. President and Chief Executive Officer Michael Combs opened the call by sa

MarketBeat

TJX Companies Q1 Earnings Call Highlights

TJX Companies (NYSE:TJX) reported first-quarter fiscal 2027 results that topped its internal expectations, driven by broad comparable sales gains, higher customer transactions and improved margins, executives said on the company’s earnings call. Chief Executive Officer and President Ernie Herrman s

MarketBeat

Mirum Pharma: A Rare Disease Growth Story to Watch

Mirum stock pulled back after earnings despite strong growth. Here’s why investors still see upside in the rare disease biotech company

MarketBeat

V.F. Q4 Earnings Call Highlights

V.F. (NYSE:VFC) executives said the apparel and footwear company ended fiscal 2026 with improving sales trends, wider margins and lower leverage, while reinstating annual guidance for fiscal 2027. President and CEO Bracken Darrell said the company “finished this year strong” and exceeded its fourth

MarketBeat

Arcos Dorados Q1 Earnings Call Highlights

Arcos Dorados (NYSE:ARCO) reported a stronger first quarter of 2026, with management saying revenue, adjusted EBITDA and cash flow improved despite a challenging consumer environment in parts of Latin America. Chief Executive Officer Luis Raganato said total revenue rose about 13% and exceeded $1.2

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Ellington Credit Q1 Earnings Call Highlights

Ellington Credit (NYSE:EARN) reported a GAAP net loss of $0.86 per share for the quarter ended March 31, 2026, as volatility in the collateralized loan obligation market weighed on asset valuations, particularly CLO equity holdings. Chief Executive Officer Larry Penn said the first calendar quarter

MarketBeat

Eagle Materials: A Dividend-Paying Brick & Mortar AI Play

Eagle Materials is in position to reverse course after solid FQ4 results highlight industrial cement demand, demand linked to datacenters and AI.

MarketBeat

Analog Devices Provides Much-Needed Pullback: How Low Can It Go?

Analog Devices is well-positioned for an AI-driven supercycle that will extend to all parts of the tech world and create positive feedback loops for business.

MarketBeat

Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data

Candel Therapeutics (NASDAQ:CADL) Chief Executive Officer Dr. Paul Peter Tak said the company remains focused on advancing its viral immunotherapy programs following newly presented prostate cancer data and as it prepares for a planned biologics license application submission by the end of the year.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Lowe's Companies Q1 Earnings Call Highlights

Lowe's Companies (NYSE:LOW) reported a modest comparable sales gain in its fiscal first quarter, with executives pointing to stronger spring execution, continued demand from professional customers and growth in online and home services as offsets to a still-pressured do-it-yourself market. The home

MarketBeat

Dorian LPG Q4 Earnings Call Highlights

Dorian LPG (NYSE:LPG) executives said the company benefited from a stronger VLGC freight market in its fiscal fourth quarter, while emphasizing a cautious capital allocation approach as the sector faces volatile geopolitics, high Panama Canal costs and an expanding orderbook. On the company’s fourt

MarketBeat

Target Q1 Earnings Call Highlights

Target (NYSE:TGT) reported stronger-than-expected first-quarter results for fiscal 2026, with executives saying early merchandising and operational changes are beginning to resonate with shoppers, while cautioning that the company remains in the early stages of a broader turnaround effort. Chief Ex

MarketBeat

Toll Brothers Q2 Earnings Call Highlights

Toll Brothers (NYSE:TOL) executives said the luxury homebuilder delivered better-than-expected fiscal second-quarter results despite a challenging demand environment, prompting the company to raise its full-year guidance across key homebuilding metrics. Executive Chairman Doug Yearley said the comp

MarketBeat

Analog Devices Q2 Earnings Call Highlights

Analog Devices (NASDAQ:ADI) reported record fiscal second-quarter 2026 results, with revenue, profitability and earnings per share exceeding the high end of the company’s prior guidance, executives said on the company’s earnings call. Chief Executive Officer and Chair Vincent Roche said the quarter

MarketBeat

Auna Q1 Earnings Call Highlights

Auna (NYSE:AUNA) reported stronger first-quarter revenue and cash flow across its regional healthcare platform, while adjusted EBITDA declined as the company absorbed revenue adjustments in Peru and higher payroll costs in Mexico and Colombia. Executive Chairman and President Jesús Zamora said the

MarketBeat

Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in severe hypertriglyceridemia, during a fireside chat at RBC Capital Markets’ 2026 Global Healthcare Conf

1 … 23 24 25 26

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.